Screener
Kymera Therapeutics KYMR Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $65M+466% | $34.37M+55.5% | $2.87M-61.2% | $2.76M-26.1% | $11.48M-55.3% | ||
| $119.48M+52.4% | $98.16M+22.3% | $83.83M+16.7% | $74.09M+22.7% | $78.39M+32.4% | ||
| $21.13M+19.7% | $20.36M+25.1% | $16.94M+3.7% | $17.34M+12.2% | $17.65M+1.6% | ||
| $140.61M+46.4% | $118.52M+22.8% | $100.77M+14.3% | $95.29M+25.6% | $96.03M+25.4% | ||
| -$75.61M+10.6% | -$84.15M-13.1% | -$97.9M-21.2% | -$92.52M-28.3% | -$84.56M-66.0% | ||
| -116.3%+620pp | -244.9%+91.9pp | -3,411%-2,319pp | -3,347.4%-1,419pp | -736.8%-538pp | ||
| $14.4M+81.2% | $14.92M+68.7% | $10.92M+9.1% | $10.35M+7.4% | $7.94M-10.4% | ||
| -$61.21M+20.1% | -$69.23M-5.6% | -$86.98M-22.9% | -$82.18M-31.5% | -$76.61M-82.1% | ||
| -94.2%+573pp | -201.5%+95.3pp | -3,030.7%-2,074pp | -2,973%-1,303pp | -667.6%-504pp | ||
| -$0.62+34.7% | -$0.71+13.4% | -$0.98-10.1% | -$0.94-14.6% | -$0.95-63.8% | ||
| -$73.58M+10.8% | -$82.13M-13.5% | -$95.86M-21.7% | -$90.37M-28.9% | -$82.47M-68.4% | ||
| -113.2%+605pp | -239%+88.5pp | -3,340.2%-2,275pp | -3,269.6%-1,395pp | -718.7%-528pp | ||
| -$75.61M+10.6% | -$84.15M-13.1% | -$97.9M-21.2% | -$92.52M-28.3% | -$84.56M-66.0% |
FAQ
- What is Kymera Therapeutics's revenue?
- Kymera Therapeutics (KYMR) generated $105.0M in revenue over the trailing twelve months, up 134.8% year over year.
- Is Kymera Therapeutics profitable?
- Kymera Therapeutics is not currently profitable: it reported a net loss of $299.6M over the trailing twelve months, a -285.3% net margin.
- What is Kymera Therapeutics's earnings per share?
- Kymera Therapeutics's diluted EPS over the trailing twelve months is $-3.25.
- Where does Kymera Therapeutics's income statement data come from?
- Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
